Premastectomy Radiotherapy and Immediate Breast Reconstruction
JAMA Network Open · 05.04.2024 · 7 (4) · e245217
DOI: 10.1001/jamanetworkopen.2024.5217 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 05.04.2024. Verfasst von Mark V Schaverien und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston. Hauptthemen laut MEDLINE: Breast Neoplasms, Mammaplasty. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Importance Premastectomy radiotherapy (PreMRT) is a new treatment sequence to avoid the adverse effects of radiotherapy on the final breast reconstruction while achieving the benefits of immediate breast reconstruction (IMBR).
Objective
To evaluate outcomes among patients who received PreMRT and regional nodal irradiation (RNI) followed by mastectomy and IMBR. Design, Setting, and Participants This was a phase 2 single-center randomized clinical trial conducted between August 3, 2018, and August 2, 2022, evaluating the feasibility and safety of PreMRT and RNI (including internal mammary lymph nodes). Patients with cT0-T3, N0-N3b breast cancer and a recommendation for radiotherapy were eligible.
Intervention
This trial evaluated outcomes after PreMRT followed by mastectomy and IMBR. Patients were randomized to receive either hypofractionated (40.05 Gy/15 fractions) or conventionally fractionated (50 Gy/25 fractions) RNI. Main Outcome and Measures The primary outcome was reconstructive failure, defined as complete autologous flap loss. Demographic, treatment, and outcomes data were collected, and associations between multiple variables and outcomes were evaluated. Analysis was performed on an intent-to-treat basis.
Results
Fifty patients were enrolled. Among 49 evaluable patients, the median age was 48 years (range, 31-72 years), and 46 patients (94%) received neoadjuvant systemic therapy. Twenty-five patients received 50 Gy in 25 fractions to the breast and 45 Gy in 25 fractions to regional nodes, and 24 patients received 40.05 Gy in 15 fractions to the breast and 37.5 Gy in 15 fractions to regional nodes, including internal mammary lymph nodes. Forty-eight patients underwent mastectomy with IMBR, at a median of 23 days (IQR, 20-28.5 days) after radiotherapy. Forty-one patients had microvascular autologous flap reconstruction, 5 underwent latissimus dorsi pedicled flap reconstruction, and 2 had tissue expander placement. There were no complete autologous flap losses, and 1 patient underwent tissue expander explantation. Eight of 48 patients (17%) had mastectomy skin flap necrosis of the treated breast, of whom 1 underwent reoperation. During follow-up (median, 29.7 months [range, 10.1-65.2 months]), there were no locoregional recurrences or distant metastasis. Conclusions and Relevance This randomized clinical trial found PreMRT and RNI followed by mastectomy and microvascular autologous flap IMBR to be feasible and safe. Based on these results, a larger randomized clinical trial of hypofractionated vs conventionally fractionated PreMRT has been started ( NCT05774678 ). Trial Registration ClinicalTrials.gov Identifier: NCT02912312
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston.
- Division of Surgery, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
- Division of Radiation Oncology, Department of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston.
- Division of Cancer Medicine, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
Förderung
- NCI NIH HHS
Zitieren
APA
Schaverien, M. V., Singh, P., Smith, B. D., Qiao, W., Akay, C. L., Bloom, E. S., Chavez-MacGregor, M., Chu, C. K., Clemens, M. W., Colen, J. S., Ehlers, R. A., Hwang, R. F., Joyner, M. M., Largo, R. D., Mericli, A. F., Mitchell, M. P., Shuck, J. W., Tamirisa, N., Tripathy, D., …, & Hoffman, K. E. (2024). Premastectomy Radiotherapy and Immediate Breast Reconstruction. JAMA Network Open, 7(4), e245217. https://doi.org/10.1001/jamanetworkopen.2024.5217
Vancouver
Schaverien MV, Singh P, Smith BD, Qiao W, Akay CL, Bloom ES, et al. Premastectomy Radiotherapy and Immediate Breast Reconstruction. JAMA Network Open. 2024;7(4):e245217. doi:10.1001/jamanetworkopen.2024.5217
BibTeX
@article{Schaverien2024,
author = {Schaverien, Mark V and Singh, Puneet and Smith, Benjamin D and Qiao, Wei and Akay, Catherine L and Bloom, Elizabeth S and Chavez-MacGregor, Mariana and Chu, Carrie K and Clemens, Mark W and Colen, Jessica S and Ehlers, Richard A and Hwang, Rosa F and Joyner, Melissa M and Largo, Rene D and Mericli, Alexander F and Mitchell, Melissa P and Shuck, John W and Tamirisa, Nina and Tripathy, Debasish and Villa, Mark T and Woodward, Wendy A and Zacharia, Rensi and Kuerer, Henry M and Hoffman, Karen E},
title = {Premastectomy Radiotherapy and Immediate Breast Reconstruction},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {4},
pages = {e245217},
doi = {10.1001/jamanetworkopen.2024.5217}
}
EUVIMED